The great promise of antiviral peptides against SARS-CoV-2

NewsGuard 100/100 Score

With the emergence of new and possibly more pathogenic variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic of coronavirus disease 2019 (COVID-19) may be far from over. And with over 3.7 million deaths recorded since the virus first emerged, the need for effective and safe antivirals has never been greater.

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

Study: Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2. Image Credit: Juan Gaertner / Shutterstock


SARS-CoV-2 infection is characterized by its unpredictable symptomatology. Asymptomatic in a very large percentage of cases, it causes symptoms in about 15% of cases. Unfortunately, it can induce a raging cytokine storm in about 5% of cases, leaving lung damage and multi-organ dysfunction in its trail as a result of dysregulated systemic inflammation.

Among the many drugs that have been deployed for the treatment of COVID-19, none have proved unequivocally effective. Remdesivir is effective only in reducing the duration of hospitalization slightly, but has no impact on mortality. Corticosteroids have potent anti-inflammatory activity, and do reduce the risk of death in severe COVID-19, but are a double-edged weapon.

Hydroxychloroquine and azithromycin are claimed to have doubtful evidence of efficacy, though most trials have been seriously flawed.

Monoclonal antibody formulations, meanwhile, are very expensive.

The virus itself mutates at a relatively rapid rate, and multiple variants are already circulating. This means that resistance to antiviral drugs is likely to emerge rapidly, indicating the need for new and novel drugs to be developed.

Attractive AMPs

AMPs fill this bill, in part, with a broad spectrum of activity against viruses as well as other pathogens. These positively charged peptides have amphipathic properties, which allow them to do their job properly.

These natural compounds are found in all higher organisms, and many of them have significant antiviral activity. Synthetic AMPs designed to mimic natural peptides can inhibit essential steps in viral activity, such as inhibiting virus-receptor binding, blocking viral adsorption, or inhibiting protein-protein interactions, for instance.

This is possible by imitating their structure to retain their biological function, but simultaneously making them more potent and selective. AMPs have four different types of structure, namely, linear α-helical peptides, β-sheet peptides, linear extension structures, and mixed α-helix and β-sheet peptides.

AMP sequences are easily engineered, making it easy to modify them to overcome mutational resistance. The use of a combination of AMPs, or AMPs with other drugs, can further reduce the risk of escape mutants, while perhaps enhancing antiviral activity by additive or synergistic effects. Finally, AMPs often stimulate the innate immune response


One excellent example of AMPs is the defensin family. These were the first antiviral AMPs to be reported, in fact, with in vitro activity against herpes simplex virus (HSV) types 1 and 2 and cytomegalovirus (CMV). Later, they have proved to protect against SARS-CoV, human immunodeficiency virus (HIV), influenza A virus, human adenovirus, human papillomavirus (HPV), HSV, and respiratory syncytial virus (RSV).

These are β-sheet AMPs which can interact with anionic phospholipids to break up lipid membranes; bind to glycoprotein or glycolipids; and thus interact with viral proteins or receptors to inhibit viral infection.

The defensin-like peptide P9R has been shown to have potent antiviral activity against enveloped viruses that depend on acidic conditions for endosomal entry into the host cells. This includes not only the highly pathogenic coronaviruses, the influenza viruses A H1N1pdm09 and H7N9.

Interestingly, P9R did not allow resistance to emerge in the influenza virus even after 40 passages. Conversely, the approved drug zanamivir became ineffective after the virus was passaged just 10 times in its presence, due to the acquisition of resistance.

It was derived from P9, which in turn comes from the mouse β-defensin 4, which shows the same mechanism of action. Short P9 derivatives have been conjugated to an HIV protein, introducing defective influenza virus genes, and thus preventing endosomal acidification.

Defensins have successfully inhibited Zika virus and MERS-CoV through different mechanisms, such as disrupting the viral membrane or inhibiting membrane fusion and thus viral entry.

The first antiviral peptide to be approved was Enfuvirtide (T-20 or Fuzeon) against HIV.

AMPs and SARS-CoV-2

Recently, another small molecule mimicking an AMP, called Brilacidin, was shown to inhibit SARS-CoV-2 infection in vitro by blocking viral entry into the host cell. In combination with remdesivir, Brilacidin had synergistic activity.

Other AMPs like P9R or P9 inhibit endosomal acidification, and thus block the early replication of SARS-CoV-2. Mucroporin-M1 disrupts the viral envelope. Human intestinal defensin 5 (HD5) is similar to a natural lectin, preventing SARS-CoV-2-receptor binding by blocking the latter.

Some AMPs also help modulate the severity of COVID-19 by their effect on early innate immunity.

Other AMPs

Many other examples of AMPs have been reported, such as urumin, from a South Indian frog, which inhibits resistant influenza A virus strains.

The Kα2-helix peptide from another inhibitor protein is active against highly pathogenic H5N1 and H1N1 strains of the influenza virus, destabilizing viral membranes, as well as RSV and vesicular stomatitis virus (VSV).

What are the future directions for AMP research?

Overall, there are over 2,000 AMPs on the AMP database DRAMP, providing a source for drug development. Among the several mechanisms of viral inhibition, those that prevent viral trafficking by inhibiting endosomal acidification are of special value against the highly pathogenic viruses of recent origin.

AMPs are relatively unlikely to trigger the rapid development of resistance. Moreover, they can be rapidly modified to overcome escape mutations. They have a high safety margin, as illustrated by the Zika virus inhibitor Z2, which was non-toxic to pregnant mice and their fetuses.

They are also non-immunogenic. However, they are more costly to produce, and short-lived. These hindrances can be overcome, for example, by adopting optimized manufacturing practices, where chemical synthesis is substituted with biosynthesis in appropriate cell lines, expressing recombinant peptides.

The researchers write:

Given the broad and potent activities of AMPs against multiple viruses, we recommend the funding of research into the development of AMPs as a new therapeutic strategy against viral diseases.”

Journal reference:
Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2021, June 07). The great promise of antiviral peptides against SARS-CoV-2. News-Medical. Retrieved on April 25, 2024 from

  • MLA

    Thomas, Liji. "The great promise of antiviral peptides against SARS-CoV-2". News-Medical. 25 April 2024. <>.

  • Chicago

    Thomas, Liji. "The great promise of antiviral peptides against SARS-CoV-2". News-Medical. (accessed April 25, 2024).

  • Harvard

    Thomas, Liji. 2021. The great promise of antiviral peptides against SARS-CoV-2. News-Medical, viewed 25 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Annual COVID-19 vaccine proves to be a wise investment for personal health and pocketbook